Nanobiotix Shares Drop 2% and Fall Below Short-Term Moving Averages
The French biotech company gives back some of its early week gains. The stock falls below its short-term moving averages in an almost stable Parisian market. The consolidation continues after the historical high recorded in mid-May.
Stock Falls Below Short-Term Moving Averages After Early Week Rebound
Nanobiotix shares decline by 2.17% to €29.74 at midday, while the SBF 120 remains nearly stable (+0.08%). The decline erases some of the rebound that started earlier in the week, following a more than 3% increase the previous day. The price falls below the MM20 (€31.92, gap -6.83%) and the MM50 (€32.23, gap -7.73%), a short-term signal that extends the digestion phase initiated after the mid-May record high. The RSI at 45 remains neutral, indicating no significant buying or selling pressure. The outlook changes dramatically over a longer horizon: the MM200 at €22.62 remains 31.5% below the current price, reflecting the annual rally that still exceeds 674%.
A Post-Record Consolidation in an Extraordinary Annual Journey
The stock loses more than 30% over a month, reflecting the magnitude of the consolidation following the mid-May peak and the global offering of shares initiated in May. This operation was followed by a strengthening of the cash reserves to €42.1 million as of March 31, 2026, through a capital increase of €86.1 million via pre-financed warrants. During the first quarter of 2026 publication (June 2, 2026), the biotech highlighted clinical advancements of JNJ-1900 (NBTXR3), particularly Phase 2 data in inoperable lung cancer, while noting as a risk the limited progress of the current standard of care in this indication. The nearest technical support is identified at €28.28, approximately 5% below the current price.
